(a)

Subsequent to April 30, 2019, the Company received $60,000, representing the outstanding gross proceeds related to the private placement disclosed in Note 10(d).

(b)

On May 15, 2019, the Company closed the first tranche of a private placement for an aggregate of 46,132,000 units, consisting of one common share and one share purchase warrant, at price of $0.25 per unit, for gross proceeds of $11,533,000. On May 30, 2019, the Company closed the last tranche of a private placement for an aggregate of 13,868,000 units, consisting of one common share and one share purchase warrant, at price of $0.25 per unit, for gross proceeds of $3,467,000. Each share purchase warrant entitles the holder to purchase one common share at a price of $0.35 per share and has an expiry term of two (2) years. Pursuant to the private placement, the Company issued 4,200,000 units, consisting of one common share and one share purchase warrant, representing 7% of the total units issued in the private placement as advisory fees. Each share purchase warrant entitles the holder to purchase one common share at a price of $0.35 per share and has an expiry term of two (2) years.

(c)

Subsequent to April 30, 2019, the Company extinguished, in full, convertible debentures totaling $2.75 million through the issuance of 595,238 common shares pursuant to the conversion of $250,000 of the convertible debentures and the repayment of the remaining $2.5 million in cash.

(d)

Subsequent to April 30, 2019, the Company placed an initial production order for 100,000 units of micellized CBD Solution with SolMic GmbH (“Solmic”). In connection with the production order, the Company made an up-front payment of EUR953,400 to Solmic.

(e)

Effective June 12, 2019, the Company cancelled 700,000 options to purchase common shares at an exercise price of US$0.70 and expiring on February 22, 2021. The Company also granted 2,700,000 options to purchase common shares at an exercise price of $0.40 and expiring on June 11, 2024.